O
12.20
0.35 (2.95%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Olema Pharmaceuticals, Inc. | Bullish | Bullish |
Stockmoo Score
0.1
|
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| 52 Weeks Range | ||
| Median | 31.00 (154.10%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 08 Aug 2024 | 31.00 (154.10%) | Buy | 12.74 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Sep 2024 | Announcement | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 21 Aug 2024 | Announcement | Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference |
| 06 Aug 2024 | Announcement | Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update |
| 02 Aug 2024 | Announcement | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 02 Jul 2024 | Announcement | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |